Business
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it will host a virtual research and development (R&D) investor event on Wednesday, July 9, 2025 at 11:00 AM ET featuring Kristina M. Deligiannidis, MD (Zucker Hillside Hospital, Northwell Health, New York), who will join company management to discuss the current treatment landscape and unmet needs in postpartum depression
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, June 23, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it will host a virtual research and development (R&D) investor event on Wednesday, July 9, 2025 at 11:00 AM ET featuring Kristina M. Deligiannidis, MD (Zucker Hillside Hospital, Northwell Health, New York), who will join company management to discuss the current treatment landscape and unmet needs in postpartum depression (PPD). To register, click here.","length":582,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Lipocine Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Lipocine Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":113,"url":"https://media.zenfs.com/en/prnewswire.com/62a81ae3d468802b850c2f8f9ddf2cd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KThUSUCVqrvKmZyz_JDnJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/62a81ae3d468802b850c2f8f9ddf2cd2","width":400,"height":113}},"href":"https://mma.prnewswire.com/media/627654/Lipocine_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"PPD is a common and serious mood disorder associated with adverse maternal and infant health outcomes. Effective, fast-acting treatment is critical for the well-being of the family.","length":181,"tagName":"p"},{"type":"text","content":"The event will highlight Lipocine's clinical programs with a focus on LPCN 1154 (BRLIZIO™)1, a bioidentical to a naturally occurring neuroactive steroid. LPCN 1154 is being developed with the potential to be the first line option for rapid symptom relief in women with PPD. LPCN 1154 is targeted to have a 48-hour treatment duration in an outpatient setting through a convenient oral form.","length":393,"tagName":"p"},{"type":"text","content":"The event will provide clinical, regulatory, and development updates, including details on the recently initiated Phase 3 registrational study which is expected to read out in Q2-2026.","length":184,"tagName":"p"},{"type":"text","content":"A live Q&A session will follow the formal presentations.","length":60,"tagName":"p"},{"type":"text","content":"About Kristina M. Deligiannidis, MD","length":35,"tagName":"p...